News

June 7, 2017June 7, 2017

Researchers Uncover New Mechanism that may ‘Turn Off’ Allergic Reactions

Asthma, News

Researchers have uncovered a method to overcome inflammation and exacerbated activity of immune T-cells caused by severe allergies, according to a report published in the journal JCI Insight. The team at The ... Read more

June 6, 2017June 6, 2017

Mechanical Ventilation Most Often Given Younger IPF Patients and Raises Risk of Death, Study Finds

Idiopathic Pulmonary Fibrosis, News

Mechanical ventilation given idiopathic pulmonary fibrosis (IPF) patients in respiratory distress is associated with a four-fold increase in hospital costs and a seven-fold increase in in-hospital mortality, a new study finds. ... Read more

June 5, 2017June 5, 2017

Irish Health Service Covers Vertex’s Cystic Fibrosis Therapies Orkambi and Kalydeco

Cystic Fibrosis, News

Hundreds of cystic fibrosis patients in Ireland have obtained national health service coverage for the Vertex Pharmaceuticals therapies Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor). The agreement between the Irish Health Service Executive and Vertex ... Read more

June 1, 2017June 1, 2017

Lung Stem Cells Offer Biomarkers for Earlier Lung Disease Diagnosis

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The characterization of a type of pulmonary stem cells in adult lung tissue might lead to earlier diagnoses of chronic lung diseases, as researchers have identified factors in the cells ... Read more

May 31, 2017May 31, 2017

Pulmonary Fibrosis Foundation Says U.S. Database Now Has 1,000 PF Patients, Half of 2017 Enrollment Target

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) has announced that 1,000 Americans with pulmonary fibrosis (PF) have enrolled in its Patient Registry. The goal is to enroll another 1,000 patients by the end of 2017 ... Read more

May 26, 2017May 26, 2017

Ofev Doubles the Chance of Improving or Stabilizing IPF, Studies Find

Idiopathic Pulmonary Fibrosis, News

Idiopathic pulmonary fibrosis (IPF) patients treated with Ofev (nintedanib) are twice as likely to improve or see their disease stabilize than untreated patients, according to a pool of data from ... Read more

May 25, 2017May 25, 2017

Esbriet Subgroup Analyses Suggest Benefits Also in Moderate and Severe IPF

Idiopathic Pulmonary Fibrosis, News

Patients with more severe idiopathic pulmonary fibrosis (IPF) also benefit from Esbriet (pirfenidone) treatment, as do IPF patients with moderate lung function impairment, according to two studies presented at the ... Read more

May 24, 2017June 19, 2017

INOpulse Nitric Oxide System Seen to Treat PH Patients with IPF and COPD Symptoms

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The INOpulse nitric oxide delivery system met its primary Phase 2 clinical trial goal of increasing the blood-vessel volume of pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to its maker, Bellerophon Therapeutics. ... Read more

May 23, 2017May 23, 2017

Adding Noninvasive Ventilator to At-home Oxygen Therapy Benefits COPD Patients

COPD, News

Adding a noninvasive ventilator to home oxygen therapy prolonged the time to hospital readmission for patients with chronic obstructive pulmonary disease (COPD) after an acute exacerbation. The study with the findings, ... Read more

May 22, 2017May 22, 2017

Galecto’s Inhaled IPF Therapy Candidate Shows Early Promise in Clinical Trial

Idiopathic Pulmonary Fibrosis, News

Inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients, Galecto Biotech reports. The results came from a Phase 1b/2a clinical trial (NCT02257177) evaluating TD139 in two parts. Phase 1b was ... Read more